-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services ...

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...

Lab is located in same building as PPD ® Laboratories’ Central Lab and will support Asia-Pacific oncology trials FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc.

NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic ...

NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for. NeoGenomics met analysts’ revenue expectations last quarter, ...